MedTrace Logo

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

NCT00801515 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2011-07-25

No results posted yet for this study

Summary

This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.

Conditions

Interventions

DRUG

Maraviroc

150 mg twice per day

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00801515 on ClinicalTrials.gov